| Name | Title | Contact Details |
|---|
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
Sarasota Orthopedic Associates has served the community for more than 40 years and is one of the most highly respected orthopedic groups in Florida. Our group of esteemed physicians are sought out for their medical and technical expertise. Sarasota Orthopedic Associates provides quality orthopedic treatment and care to thousands of patients each year.
Cohera Medical, Inc. is a rapidly growing medical device company actively developing surgical adhesives and sealants. TissuGlu Surgical Adhesive, the first synthetic adhesive approved for internal use, is an easily applied biocompatible, resorbable adhesive that requires no mixing or thawing. Indicated for the approximation of tissue layers where subcutaneous dead space exists between tissue planes in abdominoplasty, TissuGlu Surgical Adhesive has been shown to eliminate the need for postoperative surgical drains in most abdominoplasty procedures.
NantCel is an offshoot of Soon-Shiong`s NantWorks conglomerate. Developing molecular-level cell-based treatments for diseases.
Welcome to FOLX, the first digital Telehealth company that gives the LGBTQIA+ community access to quality care that’s in service of our needs and in celebration of our lives.